New Results Show Eli Lilly And Company's EBGLYSS Improved Skin And Itch Among Patients With Moderate-to-severe Atopic Dermatitis (Eczema) Who Were Previously Treated With Dupilumab; EBGLYSS Saw Improvements In Difficult-to-treat Face And Hand Dermatitis
Portfolio Pulse from Nabaparna Bhattacharya
Eli Lilly and Company's new drug, EBGLYSS, has shown promising results in improving skin and itch in patients with moderate-to-severe atopic dermatitis, particularly in difficult-to-treat areas like the face and hands. This is significant for patients previously treated with Dupilumab.
October 25, 2024 | 10:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly's EBGLYSS has demonstrated effectiveness in treating moderate-to-severe atopic dermatitis, especially in challenging areas, offering a new option for patients previously treated with Dupilumab.
The positive results of EBGLYSS in treating atopic dermatitis, especially in difficult areas, could enhance Eli Lilly's product portfolio and market position, potentially boosting investor confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100